Medicus Pharma (MDCX) director Larry Kaiser awarded 50,000 options at $0.36

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, he holds stock options for 50,000 shares. According to the grant terms, the options vest quarterly in four equal installments over one year, meaning the award becomes exercisable gradually rather than all at once.

Insights

Equity Compensation Analyst

Routine director option grant adds equity-based compensation exposure.

Director Larry Kaiser received stock options for 50,000 common shares at an exercise price of $0.36 per share, expiring on June 3, 2031. The grant cost is $0.00 per option today and reflects standard equity compensation, not an open-market purchase.

The options vest in four equal quarterly installments over one year, so economic benefits depend on continued service and future share price performance. There are no related sales or exercises disclosed, and no remaining derivative positions are listed beyond this grant, underscoring that this is a straightforward, routine award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kaiser Larry

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 50,000 options Exercise price: $0.36 per share Expiration date: June 3, 2031 +3 more

6 metrics

Options granted 50,000 options Stock Option (right to buy) grant on June 3, 2026

Exercise price $0.36 per share Conversion or exercise price of granted options

Expiration date June 3, 2031 Option term end for granted stock options

Post-grant option holdings 50,000 options Total derivative securities following transaction

Vesting schedule 4 quarterly installments over 1 year Footnote describing vesting terms

Grant price paid $0.00 per option Transaction price per option at grant

Key Terms

Stock Option (right to buy), exercise price, expiration date, vest quarterly, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.3600" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2031-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest quarterly financial

"The option is scheduled to vest quarterly in four equal installments"

underlying security financial

"underlying_security_title: "Common Shares""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaiser Larry

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		50,000		(1)	06/03/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Larry Kaiser	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Medicus Pharma (MDCX) director Larry Kaiser receive in this Form 4?

Director Larry Kaiser received a grant of stock options for 50,000 common shares. These options give him the right to buy Medicus Pharma shares at a fixed exercise price and represent equity-based compensation rather than an open-market share purchase.

What is the exercise price and term of Larry Kaiser’s Medicus Pharma options?

The stock options have an exercise price of $0.36 per common share and expire on June 3, 2031. This means Kaiser can choose to exercise the options at $0.36 any time before that expiration date, once they are vested and exercisable.

How do Larry Kaiser’s Medicus Pharma options vest over time?

The options are scheduled to vest quarterly in four equal installments over one year. This vesting schedule means 25% of the 50,000 options becomes exercisable each quarter, encouraging ongoing board service during the first year after the grant date.

Does this Medicus Pharma Form 4 show any stock sales or purchases by Larry Kaiser?

This Form 4 shows only an option grant to Larry Kaiser, not any open-market stock sales or purchases. The transaction is coded as a grant or award acquisition, reflecting compensation rather than a discretionary trade in Medicus Pharma common shares.

How many Medicus Pharma shares could Larry Kaiser acquire from this option grant?

If fully vested and exercised, the options allow Larry Kaiser to acquire 50,000 Medicus Pharma common shares. The Form 4 states that, after this grant, he holds stock options for 50,000 underlying shares linked to this award.